ResMed (RMD) 10-Q 29 Apr 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2016	Apr. 20, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Trading Symbol	rmd
Entity Registrant Name	RESMED INC
Entity Central Index Key	943,819
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		140,409,807

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 718,495	$ 717,249
Accounts receivable, net of allowance for doubtful accounts of $13,165 and $12,276 at March 31, 2016 and June 30, 2015, respectively	358,171	362,568
Inventories (note 3)	232,930	246,859
Prepaid expenses and other current assets	90,498	81,168
Total current assets	1,400,094	1,407,844
Non-current assets:
Property, plant and equipment, net (note 4)	386,771	387,758
Goodwill and other intangible assets, net (note 6)	572,900	311,403
Deferred income taxes	44,119	46,380
Other assets	40,726	28,389
Total non-current assets	1,044,516	773,930
Total assets	2,444,610	2,181,774
Current liabilities:
Accounts payable	77,642	81,112
Accrued expenses	152,403	132,976
Deferred revenue	38,481	36,097
Income taxes payable	17,982	16,278
Total current liabilities	286,508	266,463
Non-current liabilities:
Deferred income taxes	8,297	6,372
Deferred revenue	36,509	19,284
Long-term debt (note 7)	435,609	300,594
Other long-term liabilities	2,522
Income taxes payable	1,754	1,754
Total non-current liabilities	484,691	328,004
Total liabilities	$ 771,199	$ 594,467
Commitments and contingencies (note 12)
Stockholders' equity: (note 10)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
Common stock, $0.004 par value, 350,000,000 shares authorized; 181,453,812 issued and 140,367,578 outstanding at March 31, 2016 and 179,660,939 issued and 140,474,705 outstanding at June 30, 2015	$ 561	$ 562
Additional paid-in capital	1,290,929	1,228,795
Retained earnings	2,109,371	1,976,020
Treasury stock, at cost, 41,086,234 shares at March 31, 2016, and 39,186,234 shares at June 30, 2015	(1,546,611)	(1,444,554)
Accumulated other comprehensive loss	(180,839)	(173,516)
Total stockholders' equity	1,673,411	1,587,307
Total liabilities and stockholders' equity	$ 2,444,610	$ 2,181,774

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 13,165	$ 12,276
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.004	$ 0.004
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	181,453,812	179,660,939
Common stock, shares outstanding	140,367,578	140,474,705
Treasury stock, shares held	41,086,234	39,186,234

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statements Of Income [Abstract]
Net revenue	$ 453,879	$ 422,497	$ 1,320,066	$ 1,225,848
Cost of sales (excluding amortization of acquired intangible assets)	193,999	171,066	555,058	473,882
Gross profit	259,880	251,431	765,008	751,966
Operating expenses:
Selling, general and administrative	122,901	116,336	352,214	349,377
Research and development	28,109	27,024	84,271	86,342
Restructuring expenses			6,914
Amortization of acquired intangible assets	4,558	2,203	11,294	6,558
Total operating expenses	155,568	145,563	454,693	442,277
Income from operations	104,312	105,868	310,315	309,689
Other income, net:
Interest income, net	2,131	4,761	8,028	15,765
Other, net	2,553	3,729	3,791	6,346
Total other income, net	4,684	8,490	11,819	22,111
Income before income taxes	108,996	114,358	322,134	331,800
Income taxes	20,538	23,375	62,757	66,376
Net income	$ 88,458	$ 90,983	$ 259,377	$ 265,424
Basic earnings per share	$ 0.63	$ 0.65	$ 1.85	$ 1.89
Diluted earnings per share (note 2)	0.63	0.64	1.83	1.86
Dividend declared per share	$ 0.30	$ 0.28	$ 0.90	$ 0.84
Basic shares outstanding (000's)	140,187	140,792	140,140	140,341
Diluted shares outstanding (000's)	141,040	142,813	141,399	142,614

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 88,458	$ 90,983	$ 259,377	$ 265,424
Other comprehensive income (loss):
Foreign currency translation (loss) gain adjustments	80,098	(118,003)	(7,323)	(351,060)
Comprehensive income (loss)	$ 168,556	$ (27,020)	$ 252,054	$ (85,636)

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities:
Net income	$ 259,377	$ 265,424
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	59,827	55,310
Gain on divestment of business		(709)
Stock-based compensation costs	34,779	$ 34,802
Impairment of cost-method investments	750
Impairment of long-lived assets	2,815
Excess tax benefit from stock-based compensation arrangements	(13,312)	$ (20,738)
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	2,798	(14,814)
Inventories	26,012	(80,793)
Prepaid expenses, net deferred income taxes and other current assets	99	(3,487)
Accounts payable, accrued expenses and other liabilities	18,516	48,484
Net cash provided by operating activities	391,661	283,479
Cash flows from investing activities:
Purchases of property, plant and equipment	(44,133)	(50,266)
Patent registration costs	(6,891)	(7,109)
Business acquisitions, net of cash acquired	(242,645)	(26,956)
Investments in cost-method investments	(8,215)	(10,500)
Proceeds from divestiture of business		468
Payments on maturity of foreign currency contracts	(5,711)	(25,232)
Net cash used in investing activities	(307,595)	(119,595)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	16,937	23,176
Excess tax benefit from stock-based compensation arrangements	13,312	20,738
Purchases of treasury stock	(102,058)	(103,295)
Payment of business combination contingent consideration	(1,228)	(458)
Proceeds from borrowings, net of borrowing costs	310,000	160,000
Repayment of borrowings	(193,092)	(1,527)
Dividends paid	(126,026)	(117,862)
Net cash used in financing activities	(82,155)	(19,228)
Effect of exchange rate changes on cash	(665)	(184,061)
Net increase/(decrease) in cash and cash equivalents	1,246	(39,405)
Cash and cash equivalents at beginning of period	717,249	905,730
Cash and cash equivalents at end of period	718,495	866,325
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	55,679	33,831
Interest paid	4,887	4,253
Fair value of assets acquired, excluding cash	125,133	19,077
Liabilities assumed	(58,914)	(8,385)
Goodwill on acquisition	189,639	19,122
Deferred payments	(106)	(1,641)
Fair value of contingent consideration	(13,107)	(1,217)
Total cash component of purchase price	$ 242,645	$ 26,956

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2016
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	(1) Summary of Significant Accounting Policies  Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2016.  The condensed consolidated financial statements for the three and nine months ended March 31, 2016 and 201 5 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2015.  New Accounting Pronouncements  In May, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact of the adoption of ASU 2014-09 on our financial condition, results of operations and cash flows.  In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard is effective for us beginning in the first quarter of fiscal 2017. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes”, which requires entities to classify all deferred tax assets and liabilities as non-current on the balance sheet. The standard may be adopted on either a prospective or retrospective basis. The standard is effective for fiscal years beginning after December 15, 2016, and early adoption is permitted. Effective March 31, 2016, we adopted ASU 2015-17 and applied the new standard retrospectively. As a result of applying ASU 2015-17 to the previously reported Consolidated Balance Sheet as of June 30, 2015, d eferred income taxes within the t otal current assets decreased by approximately $36.3 million and the d eferred income taxes within the t otal non-current assets increased by approximately $33.9 million, respectively; d eferred income taxes within the t otal current liabilities decreased by approximately $0.8 million and the d eferred income taxes within t otal non-current liabilities decreased by approximately $1.7 million, respectively. There was no effect on our stockholders’ equity or to the consolidated statements of income as a result of this adoption.  On March 30, 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting ” , which is intended to improve the accounting for share-based payment transactions as part of the FASB’s simplification initiative. The ASU changes certain aspects of the accounting for share-based payment award transactions, including: accounting for income taxes; classification of excess tax benefits on the statement of cash flows; forfeitures; minimum statutory tax withholding requirements; and classification of employee taxes paid on the statement of cash flows when an employer withholds share s for tax-withholding purposes. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those years for public business entities. We are currently assessing the impact of the adoption of ASU 201 6 -09 on our financial condition, results of operations and cash flows. 

Earnings Per Share

Earnings Per Share	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share	(2) Earnings Per Share  Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.  Stock options and restricted stock units of 347 ,630 and Nil , for the three months ended March 31, 2016 and 2015 , respectively, and stock options and restricted stock units of 255,573 and 125,255 for the nine months ended March 31, 2016 and 2015 , respectively were not included in the computation of diluted earnings per share as the effect would have been anti-dilutive.  Basic and diluted earnings per share for the three and nine months ended March 31, 2016 and 2015 are calculated as follows (in thousands except per share data):    Three Months Ended March 31, Nine Months Ended March 31,  2016 2015 2016 2015  Numerator:  Net Income $ 88,458 $ 90,983 $ 259,377 $ 265,424  Denominator:  Basic weighted-average common shares outstanding 140,187 140,792 140,140 140,341  Effect of dilutive securities:  Stock options and restricted stock units 853 2,021 1,259 2,273  Diluted weighted average shares 141,040 142,813 141,399 142,614  Basic earnings per share $ 0.63 $ 0.65 $ 1.85 $ 1.89  Diluted earnings per share $ 0.63 $ 0.64 $ 1.83 $ 1.86 

Inventories

Inventories	9 Months Ended
	Mar. 31, 2016
Inventories [Abstract]
Inventories	(3) Inventories  Inventories were comprised of the following at March 31, 2016 and June 30, 2015 (in thousands):   March 31, 2016 June 30, 2015  Raw materials $ 73,163 $ 74,416  Work in progress 2,655 2,550  Finished goods 157,112 169,893  Total inventories $ 232,930 $ 246,859 

Property, Plant And Equipment

Property, Plant And Equipment	9 Months Ended
	Mar. 31, 2016
Property, Plant And Equipment [Abstract]
Property, Plant And Equipment	(4) Property, Plant and Equipment  Property, plant and equipment were comprised of the following as of March 31, 2016 and June 30, 2015 (in thousands):    March 31, 2016 June 30, 2015  Machinery and equipment $ 200,325 $ 198,047  Computer equipment 146,455 125,423  Furniture and fixtures 40,589 38,511  Vehicles 8,255 5,371  Clinical, demonstration and rental equipment 83,461 80,911  Leasehold improvements 34,508 31,553  Land 54,929 54,915  Buildings 233,860 235,515  802,382 770,246  Accumulated depreciation and amortization (415,611) (382,488)  Property, plant and equipment, net $ 386,771 $ 387,758 

Cost-Method Investments

Cost-Method Investments	9 Months Ended
	Mar. 31, 2016
Cost-Method Investments [Abstract]
Cost-Method Investments	 (5) Cost-Method Investments  The aggregate carrying amount of our cost-method investments at March 31, 2016 and June 30, 2015, was $33 .1 million and $ 25.6 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.  We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows . During the nine months ended March 31, 2016 and 2015 , we recognized $0.8 million and $Nil, respectively, of impairment losses related to our cost-method investments. We have determined , after the impairment charge, that the fair value of our remaining investments exceed their carrying values.  The following table shows a reconciliation of the changes in our cost-method investments during the nine months ended March 31, 2016 and 2015 (in thousands):    Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ 25,600 $ 14,850  Investments 8,215 10,500  Impairment of cost-method investments (750) -  Balance at the end of the period $ 33,065 $ 25,350 

Goodwill And Other Intangible A

Goodwill And Other Intangible Assets, Net	9 Months Ended
	Mar. 31, 2016
Goodwill And Other Intangible Assets, Net [Abstract]
Goodwill And Other Intangible Assets, Net	(6) Goodwill and Other Intangible Assets, net  Goodwill Changes in the carrying amount of goodwill for the nine months ended March 31, 2016 , and 2015 were as follows (in thousands):    Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ 264,261 $ 289,312  Business acquisition 189,639 19,122  Foreign currency translation adjustments 4,376 (52,854)  Balance at the end of the period $ 458,276 $ 255,580  Other Intangible Assets Other intangible assets were comprised of the following as of March 31, 2016 , and June 30, 2015 (in thousands):    March 31, 2016 June 30, 2015  Developed/core product technology $ 88,939 $ 67,548  Accumulated amortization (57,211) (50,373)  Developed/core product technology, net 31,728 17,175  Trade names 19,955 2,500  Accumulated amortization (3,283) (2,206)  Trade names, net 16,672 294  Non-compete agreements 3,137 1,747  Accumulated amortization (1,854) (1,704)  Non compete agreements, net 1,283 43  Customer relationships 68,603 30,538  Accumulated amortization (24,048) (19,308)  Customer relationships, net 44,555 11,230  Patents 73,670 66,585  Accumulated amortization (53,284) (48,185)  Patents, net 20,386 18,400  Total other intangibles, net $ 114,624 $ 47,142  Intangible assets consist of patents, customer relationships, trade names, non-compete agreements and developed/core product technology. We amortize intangible assets over the estimated useful life of the assets, generally between two and nine years. There are no expected residual values related to these intangible assets.

Debt

Debt	9 Months Ended
	Mar. 31, 2016
Debt [Abstract]
Debt	(7) Debt Debt at March 31, 2016 and June 30, 2015 consisted of the following (in thousands):   March 31, 2016 June 30, 2015  Long-term debt 435,609 300,594  Total debt $ 435,609 $ 300,594  Credit Facility  On October 31, 2013, we entered into a credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger. Our obligations under the credit agreement are guaranteed by ResMed Corp. and ResMed Motor Technologies Inc., two of our U.S. subsidiaries.  The credit agreement provides a $700 million senior unsecured five -year revolving credit facility, with an uncommitted option to increase the credit facility by an additional $300 million. The credit facility also includes a $25 million sublimit for letters of credit. The credit facility terminates on October 31, 2018 , when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At March 31, 2016 , the interest rate that was being charged on the outstanding principal amount was 1.4% . An applicable commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility.  When we entered into the credit agreement, we used a portion of the proceeds from the initial funding of the credit facility to repay the outstanding balance under our previous revolving credit facility with Union Bank, N.A and other lenders. On that repayment, the previous credit agreement was terminated and the commitments under the previous credit agreement were also terminated.  Our obligations under the current credit agreement are unsecured but are guaranteed by two of our U.S. subsidiaries. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio. The entire principal amount of the credit facility and any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the credit agreement. Events of default under the credit agreement include failure to make payments when due, the occurrence of a default in the performance of any covenants in the credit agreement or related documents, or certain changes of control of ResMed Inc., ResMed Corp., ResMed Motor Technologies Inc., ResMed Limited, ResMed Holdings Ltd/LLC or ResMed EAP Holdings LLC. We recently amended the terms of the c redit a greement. For a description of the amended c redit a greement, see Note 15—Subsequent Events .  At March 31, 2016 , there was $ 435.0 million outstanding under the credit agreement. In addition, at March 31, 2016, we had $0.6 million in long-term debt which w as assumed through our acquisitions.

Product Warranties

Product Warranties	9 Months Ended
	Mar. 31, 2016
Product Warranties [Abstract]
Product Warranties	(8) Product Warranties  Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the nine months ended March 31, 2016 and 2015 are as follows (in thousands):    Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ 9,823 $ 11,798  Warranty accruals for the period 9,283 4,754  Warranty costs incurred for the period (6,929) (4,821)  Foreign currency translation adjustments 106 (1,978)  Balance at the end of the period $ 12,283 $ 9,753 

Stock-Based Employee Compensati

Stock-Based Employee Compensation	9 Months Ended
	Mar. 31, 2016
Stock-Based Employee Compensation [Abstract]
Stock-Based Employee Compensation	(9) Stock-Based Employee Compensation  We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the employee stock purchase plan (the “ESPP”) using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units which contain a market condition, are estimated using a Monte-Carlo simulation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest. We estimate the fair value stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions:    Three Months Ended March 31, Nine Months Ended March 31,  2016 2015 2016 2015  Stock options:  Weighted average grant date fair value $ 11.61 $ - $ 12.18 $ 10.58  Weighted average risk-free interest rate 1.29% - 1.66% 1.60%  Expected option life in years 4.9 - 4.9 4.9  Dividend yield 2.09% - 2.06% - 2.09% 2.15% - 2.15%  Expected volatility 27% - 27% - 27% 27% - 27%   ESPP purchase rights:  Weighted average grant date fair value $ 13.78 $ 10.72 $ 13.88 $ 10.72  Weighted average risk-free interest rate 0.2% 0.1% 0.2% 0.1%  Expected option life in years 6 months 6 months 6 months 6 months  Dividend yield 2.06% 2.17% 1.99% - 2.06% 2.00% - 2.17%  Expected volatility 32% 22% 31% - 32% 22% - 24%    During the nine months ended March 31, 201 6 and 201 5 , we granted 208,000 and 216,000 performance restricted stock units (“PRSUs”), which contain a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a three -year period, up to a maximum amount to be issued under the award of 200% of the original grant. The weighted average fair value of PRSUs granted during the nine months ended March 31, 201 6 and 201 5 was estimated at $53.11 and $51.12 per PRSU, respectively, using a Monte-Carlo simulation valuation model. 

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Mar. 31, 2016
Stockholders' Equity [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity  Common Stock. We have temporarily suspended our share repurchase program due to recent acquisitions. Accordingly, we did no t repurchase any shares during the three months ended March 31, 2016. During the three months ended March 31, 2015 we repurchased 0.3 million shares at a cost of $20.3 million. Since the inception of our share repurchase programs and through March 31, 2016 , we have repurchased a total of 41.1 million shares at a cost of $1.5 billion . Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. At March 31, 2016 , 13.6 million additional shares can be repurchased under the approved share repurchase program.  Preferred Stock. In April 1997, the board of directors designated 2,000,000 shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at March 31, 2016 and June 30, 2015 .  Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the “2009 Plan”). The options have expiration dates of seven years from the date of grant and, the options and restricted stock units vest over one to four years. We have granted the options with an exercise price equal to the market value as determined at the date of grant.  The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 43.7 million shares. The number of securities remaining available for future issuance under the 2009 Plan at March 31, 2016 is 12.9 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any “full-value award,” which is any award other than a stock option, stock appreciation right or other award for which the holder pays the intrinsic value and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, that may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant’s initial year of hiring, when up to 4.5 million shares of our common stock may be granted).  At March 31, 2016 , there were $ 75.6 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.4 years . The aggregate intrinsic value of the stock-based compensation arrangements outstanding and exercisable at March 31, 2016 was $ 148.7 million and $ 38.4 million , respectively. The aggregate intrinsic value of the options exercised during the nine months ended March 31, 2016 and 2015 , was $ 36.8 million and $ 64.0 million, respectively. The following table summarizes option activity during the nine months ended March 31, 2016 :    Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 2,809,238 $ 29.63 2.5  Granted 336,176 58.22  Exercised (1,066,264) 21.95  Forfeited (27,833) 40.78  Outstanding at end of period 2,051,317 $ 38.14 2.3  Exercise price of granted options $ 58.22  Options exercisable at end of period 1,491,430 $ 32.04  The following table summarizes the activity of restricted stock units during the nine months ended March 31, 2016 :    Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 2,312,529 $ 43.65 1.2  Granted 703,227 54.88  Vested (823,564) 39.44  Expired (251,945) 38.22  Forfeited (68,323) 45.46  Outstanding at end of period 1,871,924 $ 50.39 2.39  Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors’ compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85 % of the fair market value of our common stock on the date of grant or 85 % of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $ 25,000 in common stock during any calendar year. At March 31, 2016 , the number of shares remaining available for future issuance under the ESPP is 1.4 million shares.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2016
Fair Value Measurements [Abstract]
Fair Value Measurements	(11) Fair Value Measurements  In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  The hierarchies of inputs are as follows:  · Level 1: Input prices quoted in an active market for identical financial assets or liabilities;  · Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and  · Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.  The following table summarizes our financial assets and liabilities, as at March 31, 2016 and June 30, 2015, using the valuation input hierarchy (in thousands):    Level 1 Level 2 Level 3 Total  Balances at March 31, 2016  Foreign currency hedging instruments, net $ - $ 6,777 $ - $ 6,777  Business acquisition contingent consideration $ - $ - $ (13,357) $ (13,357)  Balances at June 30, 2015  Foreign currency hedging instruments, net $ - $ 1,038 $ - $ 1,038  Business acquisition contingent consideration $ - $ - $ (1,584) $ (1,584)   We determine the fair value of our financial assets and liabilities as follows:  · Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.  · Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.  The following is a reconciliation of changes in the fair value of contingent consideration for the nine months ended March 31, 2016 and 2015 (in thousands):    Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ (1,584) $ (480)  Acquisition date fair value of contingent consideration (13,107) (1,217)  Changes in fair value included in operating income 154 132  Payments 1,228 458  Foreign currency translation adjustments (48) 33  Balance at the end of the period $ (13,357) $ (1,074)  We did not have any significant non-financial assets or liabilities measured at fair value on March 31, 2016 or June 30, 2015.

Legal Actions And Contingencies

Legal Actions And Contingencies	9 Months Ended
	Mar. 31, 2016
Legal Actions And Contingencies [Abstract]
Legal Actions And Contingencies	(12) Legal Actions and Contingencies  Litigation In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.  Obligations Under Recourse Provisions  We use independent leasing companies to provide financing to certain customers for the purchase of our products. In some cases, and within certain limits, we are liable to the leasing companies in the event of a customer default for unpaid installment receivables transferred to the leasing companies. The gross amount of receivables sold with recourse during the nine months ended March 31, 2016 and 2015 , amounted to $49.6 million and $20.1 million, respectively. The maximum potential amount of contingent liability under these arrangements at March 31, 2016 and June 30, 2015 were $10.1 million , and $7.2 million, respectively. The recourse liability recognized by us at March 31, 2016 and June 30, 2015, in relation to these arrangements was $0.6 million and $0.5 million, respectively. 

Derivative Instruments And Hedg

Derivative Instruments And Hedging Activities	9 Months Ended
	Mar. 31, 2016
Derivative Instruments And Hedging Activities [Abstract]
Derivative Instruments And Hedging Activities	(13) Derivative Instruments and Hedging Activities  We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes.  We held foreign currency instruments with notional amounts totaling $ 636.2 million and $ 576.5 million at March 31, 2016 and June 30, 2015, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to March 31 , 201 9 .  The following table summarizes the amount and location of our derivative financial instruments as of March 31, 2016 and June 30, 2015 (in thousands):    March 31, 2016 June 30, 2015 Balance Sheet Caption  Foreign currency hedging instruments $ 4,905 $ 1,644 Other assets - current  Foreign currency hedging instruments 4,201 1,348 Other assets - non current  Foreign currency hedging instruments (537) (1,954) Accrued expenses  Foreign currency hedging instruments (1,792) - Other long-term liabilities  $ 6,777 $ 1,038  The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the nine months ended March 31, 2016 and 2015 , respectively (in thousands):    Gain /(Loss) Recognized Income Statement Caption  Nine Months Ended March 31,  2016 2015  Foreign currency hedging instruments $ (1,095) $ (26,654) Other, net  Other foreign-currency-denominated transactions 4,837 32,099 Other, net  $ 3,742 $ 5,445  We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Business Combinations

Business Combinations	9 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Business Combinations	(14) Business Combinations  On October 2, 2015 we completed the acquisition of 100% of the shares in Curative Medical Technology Inc., a leading provider of non-invasive ventilation and sleep-disordered breathing medical devices and accessories in China. Curative has its manufacturing base in Suzhou, China, offices in Beijing, Germany and the United States, and a distributor network throughout China and in other select markets.  On November 6, 2015 we completed the acquisition of 100% of the shares in Maribo Medico A/S, a distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders in Denmark and the Nordics.  On November 30, 2015 we completed the acquisition of 100% of the shares in Bennett Precision Tooling Pty Ltd, a n Australian based company that designs and manufacture s tools specializ ing in applications for Liquid Silicon Rubber .  On January 29, 2016 we completed the acquisition of 100% of the shares in Inova Labs Inc. (“Inova Labs”) , a medical device company specializing in the development and commercialization of innovative oxygen therapy products.  These acquisitions have been accounted for as business combinations using purchase accounting and are included in our consolidated financial statements from their respective acquisition dates. The acquisitions , individually and collectively, are not considered a material business combination and accordingly pro forma information is not provided. The acquisitions were funded through cash on-hand and by drawing on our existing credit facility . During the three months ended March 31, 2016, we recorded $3.6 million in acquisition-related expenses including expenses associated with the acquisition of Brightree LLC which was completed on April 4, 2016, as discussed in Note 15 – Subsequent Events.  We have not completed the purchase price allocation in relation to these acquisitions as certain appraisals associated with the valuation of intangible assets and contingent consideration are not yet complete. We do not believe that the completion of this work will materially modify the preliminary purchase price allocation. We expect to complete our purchase price allocation during the quarter ending June 30, 2016. The cost of the acquisitions was allocated to the assets acquired and liabilities assumed based on estimates of their fair values at the date of acquisition. The goodwill recognized as part of these acquisitions, which is not deductible for tax purposes, main ly represents the synergies that are unique to our combined businesses and the potential for new products and services to be developed in the future. The preliminary fair values of assets acquired and liabilities assumed, and the estimated useful lives of intangible assets acquired are as follows (in thousands):    Intangible assets - useful life  Current assets $ 47,597  Property, plant and equipment 4,575  Tradenames 17,400 7 years  Non-compete 1,400 5 years  Developed technology 20,515 5 years  Customer relationships 37,303 5 to 8 years  Goodwill 189,639  Assets acquired $ 318,429   Current liabilities (19,550)  Debt assumed (20,305)  Deferred tax liabilities (19,059)  Total liabilities assumed $ (58,914)  Net assets acquired $ 259,515 

Subsequent Events

Subsequent Events	9 Months Ended
	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	(15) Subsequent Events  On April 4, 2016 (the “Closing Date”) we completed the acquisition of Brightree LLC (“Brightree”) , a lead ing provider of cloud-based clinical and business management software for the post-acute care industry , for a total purchase consideration paid of $800 million , subject to certain post-closing adjustments . This acquisition will be accounted for as a business combination using purchase accounting and will be included in our consolidated financial statements from the acquisition date. We expect that t he preliminary purchase price allocation will be completed during the quarter ending June 30 , 2016.  I n connection with the Brightree acquisition , on the Closing Date, we entered into a n a mendment to our existing revolving c redit a greement to increase the size of the revolving credit facility from $700 million to $1 billion, with an uncommitted option to increase the r evolving c redit f acility by an additional $300 million and make other modifications to provide for the acquisition of Brightree . Our obligations under the r evolving c redit a greement (as amended by the a mendment) are also guaranteed by certain of ResMed’s direct and indirect U . S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., and Inova Labs, Inc., under an unconditional guaranty. The a mendment contemplates that Brightree , Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC will be joined as guarantors with in 30 days after the c losing d ate. Our obligations under the r evolving c redit a greement remain unsecured. On the Closing Date, the proceeds from the funding of the term loan credit facility were used to pay a portion of the acquisition consideration for the Brightree acquisition, as well as to pay fees and expenses in connection with the acquisition, the amendment to the r evolving c redit a greement and the Term Loan Credit Agreement (as described below) .  On the Closing Date , in connection with the Brightree acquisition , we also entered into a credit agreement (the “term loan credit agreement”) providing a $300 million senior unsecured one -year term loan credit facility. Our obligations under the t erm l oan c redit a greement are also guaranteed by certain of ResMed’s direct and indirect U.S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., and Inova Labs, Inc., under an unconditional guaranty. The term l oan c redit a greement contemplates that Brightree , Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC will be joined as guarantors within 30 days after the C losing D ate. The t erm l oan c redit f acility terminates on April 3, 2017 , when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the term loan credit facility will bear interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Term Loan Credit Agreement) plus 0.0% to 1.0% (depending on the then-applicable leverage ratio). On the Closing Date, the proceeds from the funding of the term l oan c redit f acility were used to p ay a portion of the c onsideration for the Brightree acquisition, as well as to pay fees and expenses in connection with the acquisition , the a mendment to the revolving credit agreement and the term l oan c redit a greement.  Our obligations under the t erm loan c redit agreement are unsecured. The t erm l oan c redit a greement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of funded debt to EBITDA (as defined in the t erm l oan c redit a greement) and an interest coverage ratio. 

Summary Of Significant Accoun22

Summary Of Significant Accounting Policies (Policy)	9 Months Ended
	Mar. 31, 2016
Summary Of Significant Accounting Policies [Abstract]
Organization And Basis Of Presentation	Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2016.  The condensed consolidated financial statements for the three and nine months ended March 31, 2016 and 201 5 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2015.
New Accounting Pronouncements	New Accounting Pronouncements  In May, 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, “Revenue from Contracts with Customers”, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company beginning in the first quarter of fiscal year 2019. Early application is not permitted. We are currently assessing the impact of the adoption of ASU 2014-09 on our financial condition, results of operations and cash flows.  In April, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs". ASU 2015-03 will more closely align the presentation of debt issuance costs under U.S. GAAP with the presentation under comparable International Financial Reporting Standards (IFRS) by requiring that debt issuance costs be presented on the balance sheet as a direct deduction from the carrying amount of the related debt liability. The new standard is effective for us beginning in the first quarter of fiscal 2017. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory” which requires an entity to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in this guidance more closely align the measurement of inventory in GAAP with the measurement of inventory in IFRS. The new standard is effective for us beginning in the first quarter of fiscal 2018. We do not expect this updated standard to have a material impact on our consolidated financial statements and related disclosures.  In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes”, which requires entities to classify all deferred tax assets and liabilities as non-current on the balance sheet. The standard may be adopted on either a prospective or retrospective basis. The standard is effective for fiscal years beginning after December 15, 2016, and early adoption is permitted. Effective March 31, 2016, we adopted ASU 2015-17 and applied the new standard retrospectively. As a result of applying ASU 2015-17 to the previously reported Consolidated Balance Sheet as of June 30, 2015, d eferred income taxes within the t otal current assets decreased by approximately $36.3 million and the d eferred income taxes within the t otal non-current assets increased by approximately $33.9 million, respectively; d eferred income taxes within the t otal current liabilities decreased by approximately $0.8 million and the d eferred income taxes within t otal non-current liabilities decreased by approximately $1.7 million, respectively. There was no effect on our stockholders’ equity or to the consolidated statements of income as a result of this adoption.  On March 30, 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting ” , which is intended to improve the accounting for share-based payment transactions as part of the FASB’s simplification initiative. The ASU changes certain aspects of the accounting for share-based payment award transactions, including: accounting for income taxes; classification of excess tax benefits on the statement of cash flows; forfeitures; minimum statutory tax withholding requirements; and classification of employee taxes paid on the statement of cash flows when an employer withholds share s for tax-withholding purposes. The ASU is effective for fiscal years beginning after December 15, 2016, and interim periods within those years for public business entities. We are currently assessing the impact of the adoption of ASU 201 6 -09 on our financial condition, results of operations and cash flows.

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule Of Basic And Diluted Earnings Per Share	  Three Months Ended March 31, Nine Months Ended March 31,  2016 2015 2016 2015  Numerator:  Net Income $ 88,458 $ 90,983 $ 259,377 $ 265,424  Denominator:  Basic weighted-average common shares outstanding 140,187 140,792 140,140 140,341  Effect of dilutive securities:  Stock options and restricted stock units 853 2,021 1,259 2,273  Diluted weighted average shares 141,040 142,813 141,399 142,614  Basic earnings per share $ 0.63 $ 0.65 $ 1.85 $ 1.89  Diluted earnings per share $ 0.63 $ 0.64 $ 1.83 $ 1.86 

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Mar. 31, 2016
Inventories [Abstract]
Schedule Of Inventories	  March 31, 2016 June 30, 2015  Raw materials $ 73,163 $ 74,416  Work in progress 2,655 2,550  Finished goods 157,112 169,893  Total inventories $ 232,930 $ 246,859 

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	9 Months Ended
	Mar. 31, 2016
Property, Plant And Equipment [Abstract]
Components Of Property, Plant And Equipment	  March 31, 2016 June 30, 2015  Machinery and equipment $ 200,325 $ 198,047  Computer equipment 146,455 125,423  Furniture and fixtures 40,589 38,511  Vehicles 8,255 5,371  Clinical, demonstration and rental equipment 83,461 80,911  Leasehold improvements 34,508 31,553  Land 54,929 54,915  Buildings 233,860 235,515  802,382 770,246  Accumulated depreciation and amortization (415,611) (382,488)  Property, plant and equipment, net $ 386,771 $ 387,758 

Cost-Method Investments (Tables

Cost-Method Investments (Tables)	9 Months Ended
	Mar. 31, 2016
Cost-Method Investments [Abstract]
Schedule Of Reconciliation Of Changes In Cost-Method Investments	  Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ 25,600 $ 14,850  Investments 8,215 10,500  Impairment of cost-method investments (750) -  Balance at the end of the period $ 33,065 $ 25,350 

Goodwill And Other Intangible27

Goodwill And Other Intangible Assets, Net (Tables)	9 Months Ended
	Mar. 31, 2016
Goodwill And Other Intangible Assets, Net [Abstract]
Schedule Of Changes In Carrying Amount Of Goodwill	  Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ 264,261 $ 289,312  Business acquisition 189,639 19,122  Foreign currency translation adjustments 4,376 (52,854)  Balance at the end of the period $ 458,276 $ 255,580 
Schedule Of Other Intangible Assets	  March 31, 2016 June 30, 2015  Developed/core product technology $ 88,939 $ 67,548  Accumulated amortization (57,211) (50,373)  Developed/core product technology, net 31,728 17,175  Trade names 19,955 2,500  Accumulated amortization (3,283) (2,206)  Trade names, net 16,672 294  Non-compete agreements 3,137 1,747  Accumulated amortization (1,854) (1,704)  Non compete agreements, net 1,283 43  Customer relationships 68,603 30,538  Accumulated amortization (24,048) (19,308)  Customer relationships, net 44,555 11,230  Patents 73,670 66,585  Accumulated amortization (53,284) (48,185)  Patents, net 20,386 18,400  Total other intangibles, net $ 114,624 $ 47,142 

Debt (Tables)

Debt (Tables)	9 Months Ended
	Mar. 31, 2016
Debt [Abstract]
Schedule Of Debt	  March 31, 2016 June 30, 2015  Long-term debt 435,609 300,594  Total debt $ 435,609 $ 300,594 

Product Warranties (Tables)

Product Warranties (Tables)	9 Months Ended
	Mar. 31, 2016
Product Warranties [Abstract]
Schedule Of Changes In Liability For Warranty Costs	  Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ 9,823 $ 11,798  Warranty accruals for the period 9,283 4,754  Warranty costs incurred for the period (6,929) (4,821)  Foreign currency translation adjustments 106 (1,978)  Balance at the end of the period $ 12,283 $ 9,753 

Stock-Based Employee Compensa30

Stock-Based Employee Compensation (Tables)	9 Months Ended
	Mar. 31, 2016
Stock-Based Employee Compensation [Abstract]
Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted	  Three Months Ended March 31, Nine Months Ended March 31,  2016 2015 2016 2015  Stock options:  Weighted average grant date fair value $ 11.61 $ - $ 12.18 $ 10.58  Weighted average risk-free interest rate 1.29% - 1.66% 1.60%  Expected option life in years 4.9 - 4.9 4.9  Dividend yield 2.09% - 2.06% - 2.09% 2.15% - 2.15%  Expected volatility 27% - 27% - 27% 27% - 27%   ESPP purchase rights:  Weighted average grant date fair value $ 13.78 $ 10.72 $ 13.88 $ 10.72  Weighted average risk-free interest rate 0.2% 0.1% 0.2% 0.1%  Expected option life in years 6 months 6 months 6 months 6 months  Dividend yield 2.06% 2.17% 1.99% - 2.06% 2.00% - 2.17%  Expected volatility 32% 22% 31% - 32% 22% - 24%  

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2016
Stockholders' Equity [Abstract]
Schedule Of Option Activity	  Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 2,809,238 $ 29.63 2.5  Granted 336,176 58.22  Exercised (1,066,264) 21.95  Forfeited (27,833) 40.78  Outstanding at end of period 2,051,317 $ 38.14 2.3  Exercise price of granted options $ 58.22  Options exercisable at end of period 1,491,430 $ 32.04 
Schedule Of Activity Of Restricted Stock Units	  Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 2,312,529 $ 43.65 1.2  Granted 703,227 54.88  Vested (823,564) 39.44  Expired (251,945) 38.22  Forfeited (68,323) 45.46  Outstanding at end of period 1,871,924 $ 50.39 2.39 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2016
Fair Value Measurements [Abstract]
Summary Of Financial Assets And Liabilities	  Level 1 Level 2 Level 3 Total  Balances at March 31, 2016  Foreign currency hedging instruments, net $ - $ 6,777 $ - $ 6,777  Business acquisition contingent consideration $ - $ - $ (13,357) $ (13,357)  Balances at June 30, 2015  Foreign currency hedging instruments, net $ - $ 1,038 $ - $ 1,038  Business acquisition contingent consideration $ - $ - $ (1,584) $ (1,584) 
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs	  Nine Months Ended March 31,  2016 2015  Balance at the beginning of the period $ (1,584) $ (480)  Acquisition date fair value of contingent consideration (13,107) (1,217)  Changes in fair value included in operating income 154 132  Payments 1,228 458  Foreign currency translation adjustments (48) 33  Balance at the end of the period $ (13,357) $ (1,074) 

Derivative Instruments And He33

Derivative Instruments And Hedging Activities (Tables)	9 Months Ended
	Mar. 31, 2016
Derivative Instruments And Hedging Activities [Abstract]
Summary Of Amount And Location Of Derivative Financial Instruments	  March 31, 2016 June 30, 2015 Balance Sheet Caption  Foreign currency hedging instruments $ 4,905 $ 1,644 Other assets - current  Foreign currency hedging instruments 4,201 1,348 Other assets - non current  Foreign currency hedging instruments (537) (1,954) Accrued expenses  Foreign currency hedging instruments (1,792) - Other long-term liabilities  $ 6,777 $ 1,038 
Summary Of Gains (Losses) Associated With Derivative Financial Instruments	  Gain /(Loss) Recognized Income Statement Caption  Nine Months Ended March 31,  2016 2015  Foreign currency hedging instruments $ (1,095) $ (26,654) Other, net  Other foreign-currency-denominated transactions 4,837 32,099 Other, net  $ 3,742 $ 5,445 

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives	  Intangible assets - useful life  Current assets $ 47,597  Property, plant and equipment 4,575  Tradenames 17,400 7 years  Non-compete 1,400 5 years  Developed technology 20,515 5 years  Customer relationships 37,303 5 to 8 years  Goodwill 189,639  Assets acquired $ 318,429   Current liabilities (19,550)  Debt assumed (20,305)  Deferred tax liabilities (19,059)  Total liabilities assumed $ (58,914)  Net assets acquired $ 259,515 

Summary Of Significant Accoun35

Summary Of Significant Accounting Policies (Narrative) (Details) - ASU 2015-17 [Member] $ in Millions	Jun. 30, 2015USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease of deferred income taxes within total current assets	$ 36.3
Increase of deferred income taxes within total non-current assets	33.9
Decrease of deferred income taxes within total current liabilities	0.8
Increase of deferred income taxes within total non-current liabilities	$ 1.7

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Earnings Per Share [Abstract]
Stock options and restricted stock units not included in the computation of diluted earnings per share	347,630	0	255,573	125,255

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net income	$ 88,458	$ 90,983	$ 259,377	$ 265,424
Denominator:
Basic weighted-average common shares outstanding	140,187	140,792	140,140	140,341
Effect of dilutive securities:
Stock options and restricted stock units	853	2,021	1,259	2,273
Diluted weighted average shares	141,040	142,813	141,399	142,614
Basic earnings per share	$ 0.63	$ 0.65	$ 1.85	$ 1.89
Diluted earnings per share	$ 0.63	$ 0.64	$ 1.83	$ 1.86

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Inventories [Abstract]
Raw materials	$ 73,163	$ 74,416
Work in progress	2,655	2,550
Finished goods	157,112	169,893
Total inventories	$ 232,930	$ 246,859

Property, Plant And Equipment39

Property, Plant And Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 802,382	$ 770,246
Accumulated depreciation and amortization	(415,611)	(382,488)
Property, plant and equipment, net	386,771	387,758
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	200,325	198,047
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	146,455	125,423
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	40,589	38,511
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	8,255	5,371
Clinical, Demonstration And Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	83,461	80,911
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	34,508	31,553
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	54,929	54,915
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 233,860	$ 235,515

Cost-Method Investments (Narrat

Cost-Method Investments (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015	Jun. 30, 2014
Cost-Method Investments [Abstract]
Aggregate carrying amount of cost-method investments	$ 33,065	$ 25,350	$ 25,600	$ 14,850
Impairment losses related to cost-method investments	$ 750

Cost-Method Investments (Schedu

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cost-Method Investments [Abstract]
Balance at the beginning of the period	$ 25,600	$ 14,850
Investments	8,215	$ 10,500
Impairment of cost-method investments	(750)
Balance at the end of the period	$ 33,065	$ 25,350

Goodwill And Other Intangible42

Goodwill And Other Intangible Assets, Net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Goodwill And Other Intangible Assets, Net [Abstract]
Balance at the beginning of the period	$ 264,261	$ 289,312
Business acquisition	189,639	19,122
Foreign currency translation adjustments	4,376	(52,854)
Balance at the end of the period	$ 458,276	$ 255,580

Goodwill And Other Intangible43

Goodwill And Other Intangible Assets, Net (Schedule Of Other Intangible Assets) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Total other intangibles, net	$ 114,624	$ 47,142
Developed/Core Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	88,939	67,548
Accumulated amortization	(57,211)	(50,373)
Total other intangibles, net	31,728	17,175
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	19,955	2,500
Accumulated amortization	(3,283)	(2,206)
Total other intangibles, net	16,672	294
Non Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	3,137	1,747
Accumulated amortization	(1,854)	(1,704)
Total other intangibles, net	1,283	43
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	68,603	30,538
Accumulated amortization	(24,048)	(19,308)
Total other intangibles, net	44,555	11,230
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	73,670	66,585
Accumulated amortization	(53,284)	(48,185)
Total other intangibles, net	$ 20,386	$ 18,400
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	9 years

Debt (Narrative) (Details)

Debt (Narrative) (Details) $ in Millions	Oct. 31, 2013USD ($)entity	Mar. 31, 2016USD ($)
Debt Instrument [Line Items]
Amount outstanding under credit facility		$ 435
Assumed long-term debt from acquisitions		$ 0.6
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Number of US guarantors | entity	2
Maximum borrowing capacity	$ 700
Credit facility term, years	5 years
Uncommitted option to increase credit facility	$ 300
Credit facility termination date		Oct. 31, 2018
Interest rate on outstanding principal amount		1.40%
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.15%
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		1.00%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility		0.25%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus		2.00%

Debt (Schedule Of Debt) (Detail

Debt (Schedule Of Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Debt [Abstract]
Long-term debt	$ 435,609	$ 300,594
Total debt	$ 435,609	$ 300,594

Product Warranties (Schedule Of

Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Product Warranties [Abstract]
Balance at the beginning of the period	$ 9,823	$ 11,798
Warranty accruals for the period	9,283	4,754
Warranty costs incurred for the period	(6,929)	(4,821)
Foreign currency translation adjustments	106	(1,978)
Balance at the end of the period	$ 12,283	$ 9,753

Stock-Based Employee Compensa47

Stock-Based Employee Compensation (Narrative) (Details) - Performance Restricted Stock Units (PRSUs) [Member] - $ / shares	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance restricted stock units granted	208,000	216,000
Relative total shareholder return period	3 years	3 years
Maximum amount of performance restricted stock units to be issued, percentage of the original grant	200.00%	200.00%
Weighted average fair value of performance restricted stock units granted	$ 53.11	$ 51.12

Stock-Based Employee Compensa48

Stock-Based Employee Compensation (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) - $ / shares	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 11.61		$ 12.18	$ 10.58
Weighted average risk-free interest rate	1.29%		1.66%	1.60%
Expected option life in years	4 years 10 months 24 days		4 years 10 months 24 days	4 years 10 months 24 days
Dividend yield	2.09%
Expected volatility	27.00%
ESPP Purchase Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value	$ 13.78	$ 10.72	$ 13.88	$ 10.72
Weighted average risk-free interest rate	0.20%	0.10%	0.20%	0.10%
Expected option life in years	6 months	6 months	6 months	6 months
Dividend yield	2.06%	2.17%
Expected volatility	32.00%	22.00%
Minimum [Member] | ESPP Purchase Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield			1.99%	2.00%
Expected volatility			31.00%	22.00%
Maximum [Member] | ESPP Purchase Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield			2.06%	2.17%
Expected volatility			32.00%	24.00%

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details)	3 Months Ended		9 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)shares	Mar. 31, 2016USD ($)$ / sharesshares	Mar. 31, 2015USD ($)	Jun. 30, 2015USD ($)$ / sharesshares	Apr. 30, 1997$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares repurchased	0	300,000
Cost of common shares repurchased | $		$ 20,300,000
Additional shares that can be repurchased under the approved share repurchase program	13,600,000		13,600,000
Total number of shares repurchased pursuant to the repurchase program	41,086,234		41,086,234		39,186,234
Total cost of shares repurchased pursuant to the repurchase program | $	$ 1,546,611,000		$ 1,546,611,000		$ 1,444,554,000
Preferred stock, shares authorized	2,000,000		2,000,000		2,000,000
Preferred stock at par value | $ / shares	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares issued	0		0		0
Unrecognized compensation costs related to unvested stock-based compensation arrangements | $	$ 75,600,000		$ 75,600,000
Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements			2 years 4 months 24 days
Aggregate intrinsic value of the stock-based compensation arrangements outstanding | $	148,700,000		$ 148,700,000
Aggregate intrinsic value of the stock-based compensation arrangements exercisable | $	$ 38,400,000		38,400,000
Aggregate intrinsic value of the options exercised | $			$ 36,800,000	$ 64,000,000
Series A Junior Participating Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized						2,000,000
Preferred stock at par value | $ / shares						$ 0.01
Preferred stock, shares issued	0		0		0
Preferred stock, shares outstanding	0		0		0
2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option expiration period			7 years
Common stock authorized for issuance	43,700,000		43,700,000
Reduction in the number of shares of common stock available for issuance	2.8		2.8
Number of securities remaining available for future issuance	12,900,000		12,900,000
Maximum number of shares subject to awards granted	3,000,000		3,000,000
Number of common stock shares granted in participant's initial year of hiring	4,500,000		4,500,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities remaining available for future issuance	1,400,000		1,400,000
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant			85.00%
Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase			85.00%
Minimum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period			1 year
Minimum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period			3 months
Maximum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options and restricted stock units vesting period			4 years
Maximum [Member] | Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase program offering period			27 months
Common stock shares subscribed | $	$ 25,000		$ 25,000

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule Of Option Activity) (Details) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Stockholders' Equity [Abstract]
Options, Outstanding at beginning of period	2,809,238
Options, Granted	336,176
Options, Exercised	(1,066,264)
Options, Forfeited	(27,833)
Options, Outstanding at end of period	2,051,317	2,809,238
Options, Exercise price of granted options	$ 58.22
Options exercisable at end of period	1,491,430
Weighted Average Exercise Price, Outstanding at beginning of period	$ 29.63
Weighted Average Exercise Price, Granted	58.22
Weighted Average Exercise Price, Exercised	21.95
Weighted Average Exercise Price, Forfeited	40.78
Weighted Average Exercise Price, Outstanding at end of period	38.14	$ 29.63
Weighted Average Exercise Price, Options exercisable at end of period	$ 32.04
Weighted Average Remaining Contractual Term in Years, Outstanding	2 years 3 months 18 days	2 years 6 months

Stockholders' Equity (Schedul51

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Units, Outstanding at beginning of period	2,312,529
Restricted Stock Units, Granted	703,227
Restricted Stock Units, Vested	(823,564)
Restricted Stock Units, Expired	(251,945)
Restricted Stock Units, Forfeited	(68,323)
Restricted Stock Units, Outstanding at end of period	1,871,924	2,312,529
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$ 43.65
Weighted Average Grant-Date Fair Value, Granted	54.88
Weighted Average Grant-Date Fair Value, Vested	39.44
Weighted Average Grant-Date Fair Value, Expired	38.22
Weighted Average Grant-Date Fair Value, Forfeited	45.46
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$ 50.39	$ 43.65
Weighted Average Remaining Contractual Term in Years, Outstanding	2 years 4 months 21 days	1 year 2 months 12 days

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	$ 6,777	$ 1,038
Business acquisition contingent consideration	$ (13,357)	$ (1,584)
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	$ 6,777	$ 1,038
Business acquisition contingent consideration
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration	$ (13,357)	$ (1,584)

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Fair Value Measurements [Abstract]
Balance at the beginning of the period	$ (1,584)	$ (480)
Acquisition date fair value of contingent consideration	(13,107)	(1,217)
Changes in fair value included in operating income	154	132
Payments	1,228	458
Foreign currency translation adjustments	(48)	33
Balance at the end of the period	$ (13,357)	$ (1,074)

Legal Actions And Contingenci54

Legal Actions And Contingencies (Narrative) (Details) - Contingent Obligations Under Recourse Provisions [Member] - USD ($) $ in Millions	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Loss Contingencies [Line Items]
Receivables sold to leasing companies under debt factoring arrangements	$ 49.6	$ 20.1
Maximum potential contingent liability	10.1		$ 7.2
Recourse liability recognized	$ 0.6		$ 0.5

Derivative Instruments And He55

Derivative Instruments And Hedging Activities (Narrative) (Details) - USD ($) $ in Millions	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Derivative [Line Items]
Notional amount of foreign currency hedging contracts held	$ 636.2	$ 576.5
Foreign Currency Hedging Instruments [Member]
Derivative [Line Items]
Terms of foreign currency hedging contracts, maximum	3 years

Derivative Instruments And He56

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) - Foreign Currency Hedging Instruments [Member] - USD ($) $ in Thousands	Mar. 31, 2016	Jun. 30, 2015
Derivatives, Fair Value [Line Items]
Net foreign currency hedging instruments	$ 6,777	$ 1,038
Other Assets - Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	4,905	1,644
Other Assets - Non Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	4,201	1,348
Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, liabilities	(537)	$ (1,954)
Other Long-Term Liabilities [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, liabilities	$ (1,792)

Derivative Instruments And He57

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) - Derivatives Not Designated As Hedging Instruments [Member] - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income	$ 3,742	$ 5,445
Foreign Currency Hedging Instruments [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency hedging instruments	(1,095)	(26,654)
Other Foreign-Currency-Denominated Transactions [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other foreign-currency-denominated transactions	$ 4,837	$ 32,099

Business Combinations (Narrativ

Business Combinations (Narrative) (Details) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2016USD ($)	Mar. 31, 2016
Business Combinations [Line Items]
Acquisition-related expenses	$ 3.6
Curative Medical Technology Inc [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Oct. 2, 2015
Percentage of outstanding shares acquired	100.00%	100.00%
Maribo Medico A/S [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Nov. 6, 2015
Percentage of outstanding shares acquired	100.00%	100.00%
Bennett Precision Tooling Pty Ltd [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Nov. 30, 2015
Percentage of outstanding shares acquired	100.00%	100.00%
Inova Labs [Member]
Business Combinations [Line Items]
Date of acquisition agreement		Jan. 29, 2016
Percentage of outstanding shares acquired	100.00%	100.00%

Business Combinations (Schedule

Business Combinations (Schedule Of Preliminary Purchase Price Allocation and Preliminary Estimated Useful Lives) (Details) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Business Combinations [Line Items]
Current assets	$ 47,597
Property, plant and equipment	4,575
Goodwill	189,639	$ 19,122
Assets acquired	318,429
Current liabilities	(19,550)
Debt assumed	(20,305)
Deferred tax liabilities	(19,059)
Total liabilities assumed	(58,914)
Net assets acquired	259,515
Trade Names [Member]
Business Combinations [Line Items]
Intangible assets	$ 17,400
Intangible assets, useful life	7 years
Non-Compete [Member]
Business Combinations [Line Items]
Intangible assets	$ 1,400
Intangible assets, useful life	5 years
Developed Technology [Member]
Business Combinations [Line Items]
Intangible assets	$ 20,515
Intangible assets, useful life	5 years
Customer Relationships [Member]
Business Combinations [Line Items]
Intangible assets	$ 37,303
Customer Relationships [Member] | Minimum [Member]
Business Combinations [Line Items]
Intangible assets, useful life	5 years
Customer Relationships [Member] | Maximum [Member]
Business Combinations [Line Items]
Intangible assets, useful life	8 years

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - Subsequent Event [Member] - USD ($) $ in Millions	Apr. 04, 2016	Apr. 03, 2016
Revolving Credit Facility [Member]
Subsequent Event [Line Items]
Maximum borrowing capacity	$ 1,000	$ 700
Uncommitted option to increase credit facility	$ 300
Period after the closing date to join as guarantors	30 days
Term Loan Credit Agreement [Member]
Subsequent Event [Line Items]
Maximum borrowing capacity	$ 300
Credit facility term, years	1 year
Period after the closing date to join as guarantors	30 days
Credit facility termination date	Apr. 3, 2017
Term Loan Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Subsequent Event [Line Items]
Credit facility interest rate equal to reference rate plus	1.00%
Term Loan Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Subsequent Event [Line Items]
Credit facility interest rate equal to reference rate plus	2.00%
Term Loan Credit Agreement [Member] | Base Rate [Member] | Minimum [Member]
Subsequent Event [Line Items]
Credit facility interest rate equal to reference rate plus	0.00%
Term Loan Credit Agreement [Member] | Base Rate [Member] | Maximum [Member]
Subsequent Event [Line Items]
Credit facility interest rate equal to reference rate plus	1.00%
Brightree LLC [Member]
Subsequent Event [Line Items]
Date of acquisition agreement	Apr. 4, 2016
Total purchase price of acquisition	$ 800